The effective shelf creates a standing overhang of ~1.95M shares that selling stockholders can unload at any time. Monitor for a takedown notice (424B5) or insider selling volume spikes. The low dollar amount relative to market cap suggests limited immediate pressure, but the stock's low liquidity could amplify any selling. No catalyst or pipeline update is bundled with this filing.
Price Chart
Executive Summary
Lyell Immunopharma's S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026. This allows selling stockholders to resell up to 1,952,360 shares of common stock acquired in a March 2026 private placement. The company receives no proceeds from these sales, but the effectiveness introduces a potential overhang of ~1.95M shares that can be sold into the market at any time, representing approximately 0.6% of the current market cap of $321M — a modest but real dilution risk for a pre-revenue biotech with limited liquidity.
Key Facts
- S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026.
- Registration covers resale of 1,952,360 shares of common stock by selling stockholders.
- Selling stockholders include institutional investors ARCH Venture Fund, Gates Frontier, and Explore Investments.
- Lyell Immunopharma will not receive any proceeds from these share sales.
- Shares were originally purchased at $25.61 per share in a March 6, 2026 private placement.
- Current market cap is $321M; the registered shares represent ~0.6% of outstanding shares.
Financial Impact
Potential overhang of ~1.95M shares (~0.6% of market cap at $321M) that can be sold at any time; no proceeds to the company.
Risk Factors
- Selling stockholders may begin selling shares immediately, creating downward price pressure.
- Low trading liquidity could amplify the impact of any share sales.
- No company proceeds from sales — the overhang provides no operational benefit to offset dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002375 |
| Document: 9999999995-26-002375-index.html | 9999999995-26-002375 |
| Document: 9999999995-26-002375.txt | 9999999995-26-002375 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 25w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access